Why the study?
Does point-of-care coagulation testing with specific cut-offs reliably identify safe NOAC plasma concentrations in emergency patients compared to routine coagulation tests?
Does point-of-care coagulation testing with specific cut-offs reliably identify safe NOAC plasma concentrations in emergency patients compared to routine coagulation tests?
Answers are grounded in this paper and cite their sources.
Point-of-care coagulation testing with specific cut-offs may provide a rapid, qualitative assessment of NOAC plasma concentrations to guide emergency thrombolysis or surgery.
We have read with keen interest the updated practical guide by Steffel et al.1 For safer decision-making, we share the authors’ view on the need for rapid assessment of anticoagulation in patients under non-vitamin K antagonist oral anticoagulant (NOAC) during emergencies such as bleeding and urgent surgical intervention. Our group has been involved in studies on point-of-care coagulation testing (POCT) in acute stroke patients where rapid decision-making with respect to thrombolysis and anticoagulation reversal is vital. We acknowledge the inaccuracy of routine coagulation tests (including POCT) in quantitatively reflecting the anticoagulation status of NOAC-treated patients. This is true even if highly NOAC-sensitive reagents are used. However, to guide emergency treatment in NOAC-treated patients (i.e. can thrombolysis or surgery be initiated? should a reversal agent be administered?) only qualitative assessment is required [i.e. is the NOAC plasma concentration above or below the currently recommended thresholds (30 or 50 ng/mL) considered safe for thrombolysis or surgery?]. Using the upper limit of ‘normal’ (ULN) of these assays as reference values for selecting patients below the recommended threshold might lead to falsely considering patients ineligible for surgery and thrombolysis as eligible. This is due to an overlap between normal range results of healthy patients and test results obtained from blood samples of NOAC patients.2,3 We adopted the suggestion proposed by Lippi et al.2 and showed that by applying reagent-specific cut-offs (instead of using the ULN), routine coagulation assays could reliably identify patients with NOAC plasma concentrations <30 ng/mL.3 Assays, however, differ among laboratories and thus, cut-offs for each laboratory depending on the reagent would have to be set. Moreover, reagents for the same routine coagulation test may be changed over time which might require frequent resetting of cut-offs. This problem could be avoided by using POCT devices, which always use the same reagent, hence, facilitating the use of the same POCT-specific cut-offs worldwide. By applying POCT-specific cut-offs well below the assays’ ULN, the risk of POCT falsely indicating low levels of NOAC could be reduced to below 5% and NOAC plasma concentrations as low as 30 ng/mL could be detected in blood samples of real-life NOAC patients.4,5 At specific cut-offs, the Hemochron Signature POCT-INR and -activated clotting time (Werfen, Barcelona, Spain) has been shown to detect dabigatran, edoxaban, or rivaroxaban.4 Similarly, the CoaguChek POCT-INR (Roche, Rotkreuz, Switzerland) can detect edoxaban and rivaroxaban levels below 30 and 50 ng/mL.5 Apixaban is however, fairly unreactive to routine coagulation tests at low concentrations and can therefore not be assessed using routine coagulation assays.3–5 Although endorsed by international stroke guidelines, the recommended thresholds considered safe for surgery and thrombolysis are yet to be supported by prospective clinical data. Our POCT studies may nonetheless assist emergency physicians in qualitatively identifying patients with NOAC plasma concentrations below these thresholds. Importantly, cut-offs can easily be recalculated for any new threshold in the future. Just as for laboratory-based calibrated NOAC tests, knowing the prescribed NOAC and the last intake-time is indispensable for POCT-assay selection and right interpretation of results. Conflict of interest: S.P. received research grants from BMS/Pfizer, Boehringer-Ingelheim, Daiichi Sankyo, European Union, German Federal Joint Committee Innovation Fund, and German Federal Ministry of Education and Research, and speakers’ honoraria/consulting fees from AstraZeneca, Bayer, Boehringer-Ingelheim, BMS/Pfizer, Daiichi Sankyo, Portola, and Werfen. J.M. reports no conflict of interest.
No takes yet. Share an insight, caveat, or question.
Mbroh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: